Market Cap | 273.67M | P/E | - | EPS this Y | -42.30% | Ern Qtrly Grth | - |
Income | -32.74M | Forward P/E | -2.79 | EPS next Y | -32.40% | 50D Avg Chg | 27.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -14.00% |
Dividend | N/A | Price/Book | 0.95 | EPS next 5Y | - | 52W High Chg | -72.00% |
Recommedations | 2.00 | Quick Ratio | 40.20 | Shares Outstanding | 41.10M | 52W Low Chg | 81.00% |
Insider Own | 9.92% | ROA | -10.56% | Shares Float | 2.58M | Beta | 2.92 |
Inst Own | 104.00% | ROE | -12.25% | Shares Shorted/Prior | 1.88M/1.78M | Price | 6.78 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 114,546 | Target Price | 19.00 |
Oper. Margin | - | Earnings Date | - | Volume | 69,363 | Change | -1.02% |
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Morgan Stanley | Overweight | Aug 9, 24 |
Stifel | Buy | Jun 18, 24 |
Raymond James | Outperform | Jun 7, 24 |
Morgan Stanley | Equal-Weight | Aug 11, 23 |
Morgan Stanley | Equal-Weight | Dec 16, 22 |
Jefferies | Hold | Dec 16, 22 |
Jefferies | Buy | Oct 10, 22 |
Morgan Stanley | Overweight | Oct 10, 22 |
Cowen & Co. | Outperform | Oct 10, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
BVF PARTNERS L P/IL | 10% Owner 10% Owner | Dec 20 | Buy | 4.11 | 214,063 | 879,799 | 241,309 | 12/22/22 |
ORBIMED ADVISORS LLC | Director Director | Sep 19 | Buy | 17 | 300,000 | 5,100,000 | 5,779,071 | 09/21/22 |
Bonita David P | Director Director | Sep 19 | Buy | 17 | 300,000 | 5,100,000 | 5,779,071 | 09/21/22 |
Atlas Venture Fund XI, L.P. | 10% Owner 10% Owner | Sep 19 | Buy | 17 | 300,000 | 5,100,000 | 10,313,763 | 09/19/22 |